Evidence map›Paper›PMID 41593049›Full record

ArticleOncogenesis2026

Common gene mutations in 103 authenticated colorectal cancer cell lines.

Christian Kranjec, Ina A Eilertsen, Luís Nunes, Seyed H Moosavi, Kaja C G Berg, Mette Eknæs, Merete Hektoen, Barbara Niederdorfer, Guro E Lind, Rolf I Skotheim and 2 more

Abstract read
In one paragraph

Article in Oncogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christian Kranjec *Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. christian.kranjec@ous-research.no.ORCID http://orcid.org/0000-0001-9713-7406
Ina A Eilertsen *Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ina.eilertsen@ous-research.no.
Luís NunesDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-3391-1607
Seyed H MoosaviDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-0533-7476
Kaja C G BergDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Mette EknæsDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Merete HektoenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Barbara NiederdorferDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Guro E LindDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Rolf I SkotheimDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-5609-4048
Anita SveenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-8219-6251
Ragnhild A LotheDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-1693-1032

Funding

Kreftforeningen (Norwegian Cancer Society) 223319-2021Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2021058Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2023101Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2024108Norges Forskningsråd (Research Council of Norway) 287899
6 · The paper itself

Abstract

Colorectal cancer (CRC) cell lines represent the main molecular subtypes of tumors and are valuable models for preclinical investigations. However, cell lines can diverge over time and careful selection of models based on their molecular features is key. We have authenticated 103 commonly used CRC cell lines and present the mutation profiles of 20 CRC-relevant genes sequenced to an average depth of 575 times coverage. The cell lines reflected the distinct mutation patterns of hypermutation phenotypes associated with microsatellite instability and pathogenic POLE mutations. Hypermutated cell lines appeared to have a stronger mutational divergence and more frequent subclonal mutations, while mutations not associated with hypermutation were more frequently homozygous or hemizygous, classified as pathogenic, and subject to stronger selection pressure. Loss of heterozygosity at mutated loci was primarily observed in tumor suppressor genes. Genetic interactions based on co-occurring mutations identified cell lines representative of particularly aggressive subtypes of CRC, including concurrent BRAF p.V600 and truncating APC mutations, as well as APC/TP53/RAS triple mutations with double hits of APC. This study provides a resource to guide the selection of cell lines for functional studies of CRC, and detailed mutation data including classifications of pathogenicity, variant allele frequencies and illustrations of the mutation distribution along the length of encoded proteins are included.

Identifiers

PMID41593049
PMCPMC12901148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.